Visiting Research Fellow
Joe Kean is one of the Operational Team Managers at the Bridge Project in Bradford, a charity that supports families and individuals affected by substance misuse. His previous role was as the regional Steroid Project Lead in the north east for Lifeline. He is the current chair for the Yorkshire and Humberside Steroids and IPED Consultation and Reference Group, a Public Health Advisory Committee Co-opted Member for recent update of NICE Guidance PH52 and he has an MSc in Contemporary Issues in Drug Use. He considers himself fortunate to have undertaken research projects and received subsequent co-authorship alongside (among others) Professor Harrison Pope and Dr Gen Kanayama from Harvard Medical School. Alongside his background in the social services sector he has also worked in the fitness industry for over 10 years, is a fully qualified personal trainer and L3 nutritionist, and a nationally competitive power lifter (in a tested federation of course!).
Joseph Kean's Papers
Illicit and over-the-counter codeine dependence after acute back pain-successful treatment and ongoing recovery after buprenorphine/naloxone taper
Heroin Addiction and Related Clinical Problems, Published Ahead of Print, October 18, 2015.
Abstract: Increased prescribing of opioids for pain has been associated with an increase in dependency and associated morbidity and mortality. There are no evidence-based guidelines to direct the treatment of prescription or over-the-counter codeine dependency, including the use of maintenance and tapered dosing, or its use in conjunction with psychosocial interventions (PSI). Here we report the case of a family man who developed opioid analgesic dependence after being prescribed opioids for acute back pain. After his repeat prescription was stopped, he sourced both illicit and over-the-counter codeine. After 4 years of escalating use to a daily codeine dose of 1250 mg, he presented to a substance misuse service, The Bridge Project, Bradford. After successful induction and stabilisation on buprenorphine/naloxone (8 mg/2 mg) over the course of one week, our client successfully tapered over a 4-month period. He remained in work during treatment, and experienced side effects that were limited to headaches and some depressive thoughts. Opioid substitution treatment—buprenorphine/naloxone within a holistic Change Programme that included structured behavioural change psychosocial interventions—was successful, supporting slow taper across a 4-month period conducted within Unity Recovery Centre, part of the Bridge Project.
An exploratory study of image and performance enhancement drug use in a male British South Asian community.
INTERNATIONAL JOURNAL OF DRUG POLICY, 26(9), 860-867. doi:10.1016/j.drugpo.2015.03.002, 2015.
Abstract: Consumerism of image and performance enhancement drugs (IPEDs) is a world-wide public health concern. Given anecdotal reporting of increased normalisation of IPED use and uptake of British South Asian male IPED users at UK needle and syringe exchange services, the study aimed to explore use of IPEDs among this under-researched ethnic group.
Dr Charles Cornford, Joseph Kean, Adam Nash
International Journal of Drug Policy Volume 25, Issue 5, Pages 928–930, 2014.
Introduction: Anabolic–androgenic steroids (AAS), colloquially called ‘steroids’, are commonly used drugs by young males (McVeigh, Beynon, & Bellis, 2003). Known associations with AAS use include poor peer relations and poor self-esteem (Kindlundh, Hagekull, Isacson, & Nyberg, 2001), physical abuse, mental abuse and social disadvantage (Skarberg & Engstrom, 2007). Various studies have also noted the association with illicit drugs including heroin and other opiates (Buckman et al., 2013, Dodge and Hoagland, 2011, Hakansson et al., 2012, Kindlundh et al., 2001, McCabe et al., 2007 and Petersson et al., 2010). There are several possible explanations for the association with opiate use. One possible explanation is a common association with criminality and deprivation (Gårevik and Rane, 2010 and Skarberg and Engstrom, 2007). A second possible explanation is that heroin might depress gonadotropin-releasing hormone, reduce endogenous testosterone (Quaglio et al., 2008) and therefore predispose the individual to replacement through AAS. A further possible explanation is that both may share similar hedonistic neuropathways; this has been suggested as the reason for the high prevalence of opiate users in a group of AAS users with features of dependence compared to a group of AAS users without features of dependence (Kanayama, Hudson, & Pope, 2009). Further reasons though for the association between heroin and AAS use may lie in the social and cultural context in which heroin is used. This paper draws on findings from a qualitative study of AAS users to provide socio-cultural explanations for the link between AAS and heroin use.